Compare Heron Therapeutics Inc (HRTX) vs Vanguard S&P 500 ETF (VOO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Vanguard S&P 500 ETF — how do they compare? Heron Therapeutics Inc trades at $0.37 (market cap $74.04M), while Vanguard S&P 500 ETF trades at $714.56 (market cap $1.80T). The key difference: Vanguard S&P 500 ETF is far larger — about 24311.2× Heron Therapeutics Inc's market cap, and Vanguard S&P 500 ETF is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and Vanguard S&P 500 ETF for 55 Days on average.
| HRTX | VOO | |
|---|---|---|
Market Cap | $74.04M | $1.80T |
Volume | 3,668,095 | 4,660,398 |
Sector | Health | Broad Market / Factor |
52-Week High | $1.49 | $716.17 |
52-Week Low | $0.27 | $580.93 |
Typical Hold Time | 35 Days | 55 Days |
Enterprise Value | $180.78M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.39, up 17.58% today, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7 million but missed EPS estimates with a $0.03 loss. Despite negative profitability metrics, analyst consensus remains strongly positive with 89% buy ratings. Recent news highlights ongoing comparisons with peers and earnings performance discussions.
The outlook is mixed: strong analyst support and technical momentum suggest potential upside, but persistent losses and high valuation ratios pose significant risks. Investment opportunity hinges on revenue growth translating to profitability, while key risks include execution challenges and competitive pressures in the biotechnology sector.
VOO trades at $714.42, down 0.24% on the day, with a bullish technical signal from moving averages but neutral oscillators. The ETF's dividend yield is modest, and recent news highlights its role in long-term wealth building amid expectations of slowing S&P 500 profit growth. Short interest increased 46.9% in September, indicating some bearish sentiment.
The outlook for VOO remains positive for buy-and-hold investors, supported by its low-cost exposure to the S&P 500. Risks include macroeconomic headwinds from potential Fed rate hikes and elevated short interest. Analyst consensus favors long-term holding, with the ETF seen as a core portfolio component for diversification.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Vanguard S&P 500 ETF
VOO is a foundational ETF that tracks the S&P 500 Index, providing exposure to 500 of the largest and most established companies in the United States. Renowned for its ultra-low expense ratio and tax efficiency, it serves as a core building block for long-term investors seeking to capture the total return of the U.S. large-cap market in a single, highly liquid vehicle.
Read more on VOO →
